Announcements Trials

Browse Landscape

Phase

Phase 3 1 Phase 2 1 Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Uterine Cervical Neoplasms 1

Interventions

pembrolizumab 133 Carboplatin 132 Cisplatin 119 Paclitaxel 104 Gemcitabine 89 Specimen Handling 82 Magnetic Resonance Spectroscopy 82 Docetaxel 73 Dexamethasone 60 Cyclophosphamide 60 Pemetrexed 57 durvalumab 55 Bevacizumab 55 Capecitabine 54 Radiotherapy 51 Doxorubicin 51 Oxaliplatin 50 Fluorouracil 48 Radiation 47 Rituximab 43 Leucovorin 43 Vincristine 41 Lenalidomide 40 Etoposide 39 atezolizumab 37 Nivolumab 37 Letrozole 36 130-nm albumin-bound paclitaxel 32 Bortezomib 31 Prednisone 30

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × tisotumab vedotin × 90 days × Clear all

NCT06459180 2026-05-27

TroFuse-020

Merck Sharp & Dohme LLC

Phase 3 Active not recruiting

Uterine Cervical Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡